Senator Investment Group LP Boosted Jazz Pharmaceuticals Plc (JAZZ) Holding by $43.80 Million; Ack Asset Management Has Raised Continental Building Product (CBPX) Holding by $1.50 Million; Market Value Rose

February 15, 2018 - By Marie Mckinney

Doug Silverman increased its stake in Jazz Pharmaceuticals Plc (JAZZ) by 30% based on its latest 2017Q3 regulatory filing with the SEC. Senator Investment Group Lp bought 300,000 shares as the company’s stock rose 8.72% with the market. The hedge fund run by Doug Silverman held 1.30M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $190.13 million, up from 1.00M at the end of the previous reported quarter. Senator Investment Group Lp who had been investing in Jazz Pharmaceuticals Plc for a number of months, seems to be bullish on the $8.65 billion market cap company. The stock decreased 1.06% or $1.54 during the last trading session, reaching $144.3. About 91,045 shares traded. Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has risen 1.25% since February 15, 2017 and is uptrending. It has underperformed by 15.45% the S&P500.

Richard S. Meisenberg increased its stake in Continental Building Product (CBPX) by 12.05% based on its latest 2017Q3 regulatory filing with the SEC. Ack Asset Management Llc bought 57,800 shares as the company’s stock rose 2.79% with the market. The hedge fund run by Richard S. Meisenberg held 537,300 shares of the capital goods company at the end of 2017Q3, valued at $13.97 million, up from 479,500 at the end of the previous reported quarter. Ack Asset Management Llc who had been investing in Continental Building Product for a number of months, seems to be bullish on the $1.03 billion market cap company. The stock decreased 1.45% or $0.4 during the last trading session, reaching $27.25. About 81,681 shares traded. Continental Building Products, Inc. (NYSE:CBPX) has risen 13.56% since February 15, 2017 and is uptrending. It has underperformed by 3.14% the S&P500.

Investors sentiment decreased to 1.03 in Q3 2017. Its down 0.36, from 1.39 in 2017Q2. It dropped, as 39 investors sold JAZZ shares while 82 reduced holdings. 31 funds opened positions while 94 raised stakes. 53.58 million shares or 3.54% more from 51.74 million shares in 2017Q2 were reported. Lpl Finance Limited Liability Corporation reported 3,609 shares. Neuberger Berman Gp Ltd owns 117,345 shares. Daiwa Grp Incorporated invested in 1,650 shares. 8.04M were accumulated by Fmr Ltd Liability Corporation. Mitsubishi Ufj Tru Bk reported 0.03% stake. Federated Pa holds 0.01% or 19,200 shares. Moreover, Commonwealth Bankshares Of Australia has 0% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) for 730 shares. Commonwealth Equity Service has 0% invested in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). The Connecticut-based Ardsley Advisory Ptnrs has invested 1.5% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). J Goldman Co Ltd Partnership accumulated 7,500 shares. Point72 Asset Mgmt Ltd Partnership reported 0.05% stake. 36,225 were reported by Aviva Public Limited Company. Westpac Corporation has invested 0.01% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Hillsdale Inv Management has invested 0.01% in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). Adage Capital Ptnrs Gp Limited Liability Company reported 325,000 shares stake.

Senator Investment Group Lp, which manages about $11.90 billion and $7.52B US Long portfolio, decreased its stake in Altaba Inc by 2.71 million shares to 520,600 shares, valued at $34.49 million in 2017Q3, according to the filing. It also reduced its holding in Acadia Pharmaceuticals Inc (NASDAQ:ACAD) by 556,262 shares in the quarter, leaving it with 1.44M shares, and cut its stake in Sba Communications Corp New.

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 16 have Buy rating, 0 Sell and 5 Hold. Therefore 76% are positive. Jazz Pharmaceuticals had 71 analyst reports since August 3, 2015 according to SRatingsIntel. As per Wednesday, November 25, the company rating was initiated by Bernstein. The firm earned “Buy” rating on Wednesday, November 8 by UBS. The firm has “Buy” rating given on Tuesday, December 5 by FBR Capital. On Wednesday, February 24 the stock rating was maintained by Mizuho with “Neutral”. The rating was maintained by BMO Capital Markets with “Buy” on Wednesday, June 7. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) earned “Buy” rating by Stifel Nicolaus on Wednesday, February 24. Piper Jaffray maintained Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) on Friday, October 20 with “Buy” rating. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) earned “Buy” rating by Leerink Swann on Tuesday, January 2. The stock of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) earned “Buy” rating by Deutsche Bank on Monday, July 17. The firm earned “Buy” rating on Thursday, July 27 by Cantor Fitzgerald.

Since August 14, 2017, it had 0 insider buys, and 8 insider sales for $2.23 million activity. Another trade for 700 shares valued at $106,512 was made by Young Matthew P. on Tuesday, January 16. COZADD BRUCE C sold 3,000 shares worth $450,000. On Monday, December 11 MILLER MICHAEL PATRICK sold $27,830 worth of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) or 200 shares. 1,304 shares were sold by Treacy Paul, worth $186,884 on Monday, August 14.

Among 10 analysts covering Continental Building Products (NYSE:CBPX), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Continental Building Products had 30 analyst reports since August 23, 2015 according to SRatingsIntel. Citigroup maintained the stock with “Neutral” rating in Thursday, January 25 report. As per Monday, January 8, the company rating was downgraded by SunTrust. The company was initiated on Friday, January 6 by Barclays Capital. The stock has “Neutral” rating by Seaport Global Securities on Tuesday, November 22. Deutsche Bank maintained it with “Hold” rating and $21 target in Monday, May 16 report. The stock of Continental Building Products, Inc. (NYSE:CBPX) earned “Buy” rating by RBC Capital Markets on Monday, June 19. The stock of Continental Building Products, Inc. (NYSE:CBPX) has “Overweight” rating given on Thursday, June 2 by Barclays Capital. The firm has “Buy” rating by Sterne Agee CRT given on Monday, November 16. The stock has “Neutral” rating by Citigroup on Thursday, August 4. Credit Suisse maintained the shares of CBPX in report on Tuesday, February 23 with “Outperform” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>